Table 1

Demographic information
PSP(n = 19) PD(n = 20) HOA(n = 20)
Age, yrs 69.1 (8.7) 68.3 (7.9) 71.8 (4.1) n/s
Male, n(%) 16 (84) 16 (80) 7 (35) P = 0.001
Height, cm 170.6 (8.2) 171.8 (8.0) 166.6 (6.3) n/s
Weight, kg 80.5 (13.5) 78.3 (10.2) 68.4 (11.5) F2,56 = 5.9, P = 0.01
Symptom duration, yrs 4.3 (2.7) 6.6 (5.8) - n/s
Disease severity 41.7 (17.2) 14.4 (16.7) - -
Normalized speed 1.03 (0.27) 1.28 (0.22) 1.54 (0.16) F2,56 = 25.8, P < 0.001
Normalized stride length 1.2 (0.2) 1.4 (0.2) 1.6 (0.1) F2,56 = 25.6, P < 0.001
Cadence (steps/min) 103.6 (9.3) 109.7 (6.9) 113.4 (7.0) F2,56 = 7.9, P = 0.001
Cadence (steps/min)* 119.8 (15.4) 108.9 (18.9) 92.7 (9.5) F2,56= 15.9, P <0.001
DS (%)* 31.1 (4.6) 27.9 (3.0) 25.6 (2.7) F2,56 = 12.2, P < 0.001
Step width (cm)* 11.4 (4.2) 9.0 (2.9) 8.5 (2.9) F2,56 = 4.0, P = 0.02
Stance time variability (sec)* 0.024 (0.009) 0.018 (0.008) 0.025 (0.013) n/s
Stride length variability (cm)* 3.2 (1.7) 2.4 (1.2) 2.8 (1.6) n/s

Mean (standard deviation, SD) for each group. Disease severity was measured using PSP Rating Scale for PSP participants (0=no symptoms – 100) and Unified Parkinson’s Disease Rating Scale – motor subsection (UPDRS III) for PD participants (0=no symptoms – 56). Mean (SD) normalized speed, normalized stride length and cadence for preferred speed walks. Mean (SD) of other gait parameters for the walk with normalized stride length closest to 1.4.

* Determined from walk with normalized stride length closest to 1.4. PSP progressive supranuclear palsy, PD Parkinson’s disease, HOA healthy older adult, DS double support percentage of gait cycle, n/s not statistically significant.

Egerton et al.

Egerton et al. BMC Neurology 2012 12:116   doi:10.1186/1471-2377-12-116

Open Data